What is zasocitinib, the once-daily psoriasis pill the FDA is fast-tracking?

Zasocitinib is an investigational once-daily oral medicine for moderate-to-severe plaque psoriasis; the FDA has accepted its application for Priority Review.…

Zasocitinib is an investigational once-daily oral medicine for moderate-to-severe plaque psoriasis; the FDA has accepted its application for Priority Review. That status shortens the agency’s review target because the therapy may offer a meaningful advance—it is not an approval and does not prove the drug is right for any individual. Patients should discuss established options with a dermatologist and wait for the FDA decision and full prescribing information before treating it as available.

Why Priority Review is not the same as approval

Priority Review is a timetable, not a verdict. The FDA accepts an application and aims to act faster when a therapy may offer a significant improvement for a serious condition. Reviewers still examine the trial evidence, safety findings, and manufacturing information, and they can approve, ask for more information, or decline. Until that decision and final prescribing information are published, the medicine remains investigational.

What to do, step by step

1. Read headlines carefully: “accepted for review” means evaluation has begun, not that a drug is approved.
2. Look for what the trials actually measured and who took part in them.
3. Wait for the FDA decision and the full prescribing information before drawing conclusions.
4. Discuss any treatment questions with your own dermatologist, who knows your full medical history.